CD8A and hepatocellular carcinoma: As revealed by the increase in CD8+ T cells, anti-PD-1 therapy could be effective against the tumor, and CD8+ T cells could contribute to tumor cell death [43, 44].Consequently, we conclude that HCC patients with more immune cell infiltration can be better selected for immunotherapy.